Investor's Business Daily on MSN7h
Incyte Loses 9% As Skin Disease Drug Looks 'Viable, But Not Competitive'
Incyte's skin disease treatment looks "viable, but not competitive with biologics," an analyst said Monday as Incyte stock fell.
2BFLY : Butterfly Network Is 'Pioneering Digital Ultrasound Market,&#...
Butterfly Network exceeded Q4 estimates with 35% revenue growth. William Blair sees strong upside, citing homecare potential ...
Palantir Technologies (PLTR): Among the Best Reddit Stocks to Invest In
We recently published a list of 11 Best Reddit Stocks to Invest In. In this article, we are going to take a look at where ...
William Blair Upgrades DocuSign (DOCU) Stock on IAM Platform’s Potential
Software company DocuSign (DOCU) scored a rating upgrade from Hold to Buy from William Blair, thanks to the optimism about ...
Finbold12h
Analyst uprgades Palantir stock
A Wall Street analyst believes Palantir's (NASDAQ: PLTR) expanding artificial intelligence (AI) ecosystem, marked by major ...
William Blair Reaffirms Their Hold Rating on Science Applications (SAIC)
William Blair analyst Louie DiPalma maintained a Hold rating on Science Applications (SAIC – Research Report) today. The company’s shares ...
What is William Blair’s Estimate for Sprinklr Q1 Earnings?
Equities research analysts at William Blair issued their Q1 2026 earnings estimates for shares of Sprinklr in a note issued ...
William Blair Issues Pessimistic Outlook for ARCT Earnings
William Blair cut their Q1 2025 earnings per share (EPS) estimates for Arcturus Therapeutics in a report issued on Thursday, March 13th. William Blair analyst M. Minter now forecasts that the ...